Corvus Highlights Soquelitinib's Potential in Immune Disease Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CRVS?
"We started the year with strong momentum for soquelitinib, our selective ITK inhibitor that we believe is well positioned to improve therapy for a broad range of patients with atopic dermatitis, other immune diseases and cancers," said Richard A. Miller, co-founder, president and chief executive officer of Corvus. "The data generated from our clinical and preclinical work support soquelitinib's potential to provide a new treatment paradigm for these diseases based on a rebalancing of the immune system. We will share additional data supporting this mechanism at the upcoming annual meeting of the Society for Investigative Dermatology, where we are reviewing data from our Phase 1 atopic dermatitis trial in two oral presentations. Looking forward, we are focused on our ongoing and planned soquelitinib clinical trials, including the initiation of new Phase 2 studies in hidradenitis suppurativa and asthma anticipated later this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRVS
Wall Street analysts forecast CRVS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.590
Low
11.00
Averages
13.33
High
16.00
Current: 14.590
Low
11.00
Averages
13.33
High
16.00
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corvus Pharmaceuticals Appoints New Board Member
- New Board Member: Corvus Pharmaceuticals has appointed Dr. Andrew C. Chan to its Board of Directors, bringing 25 years of experience from Genentech where he led the development of several FDA-approved drugs, enhancing the company's expertise in immune modulation and cancer treatment.
- Enhanced Scientific Perspective: Dr. Chan's addition is expected to elevate the scientific perspective of the board, supporting the company's strategy in ITK inhibition and immune modulation, which is anticipated to drive the development of soquelitinib and strengthen market competitiveness in treating immune diseases and cancer.
- Rich Professional Background: Dr. Chan's deep expertise in immunology and his remarkable achievements in academia and industry, particularly in T cell signaling, will provide significant strategic value to Corvus's research and development efforts.
- Clinical Trial Prospects: Soquelitinib, an investigational oral small molecule drug, is currently undergoing a registration Phase 3 clinical trial for relapsed/refractory PTCL, expected to offer a new treatment mechanism for various immune diseases, further solidifying the company's market position.
See More
Corvus Pharmaceuticals Unveils New Drug Data at SID Meeting
- Clinical Trial Progress: Corvus Pharmaceuticals will showcase Phase 1 clinical trial data for soquelitinib at the investor meeting on May 14, 2026, including new immunologic and biomarker data supporting drug-free remissions, which could enhance the company's competitive position in dermatological treatments.
- Key Meeting Arrangement: The meeting will be hosted by CEO Richard A. Miller, M.D., featuring experts from Stanford University discussing the drug's mechanism and its application in atopic dermatitis, likely attracting significant attention from investors and analysts, thereby boosting market confidence.
- Financial Reporting Schedule: The company plans to release its first-quarter 2026 financial results on May 7, 2026, without a conference call, indicating a focus on direct communication with investors, which may influence shareholder expectations regarding the company's future performance.
- New Drug Development Outlook: As a selective ITK inhibitor, soquelitinib is undergoing multiple clinical trials, and if successful, it could open new market opportunities for the company in immunotherapy, particularly in treating relapsed/refractory PTCL and atopic dermatitis.
See More
Corvus' Oral Therapy Potential Underestimated by Analysts
- Significant Clinical Results: Corvus' Soquelitinib demonstrated impressive early trial results for atopic dermatitis, with 75% of patients achieving at least a 75% improvement and 25% experiencing over 90% improvement, indicating its potential as a leading oral therapy in the market.
- Stock Price Surge: Following a bullish analyst call, shares of Corvus Pharmaceuticals (CRVS) jumped nearly 12% on Friday, breaking above their 50-day moving average for the first time since March 13, reflecting increased market confidence in the potential of its oral drug.
- Goldman Sachs Upgrade: Goldman Sachs initiated coverage of Corvus with a 'Buy' rating and a price target of $40, representing a 138% upside from current levels, highlighting the company's competitive edge in the post-Dupixent atopic dermatitis market.
- Investor Sentiment Shift: Retail sentiment for CRVS on Stocktwits shifted from 'bearish' to 'bullish' with high message volumes, as some users anticipate the stock could climb to $100 over the next 12-18 months, indicating optimism about Corvus' future prospects.
See More
Goldman Sachs Initiates Buy on Corvus with $40 Target
- Goldman Coverage Launch: Goldman Sachs has initiated coverage on Corvus Pharmaceuticals (CRVS) with a Buy rating and a $40 price target, with analyst Paul Choi highlighting the pipeline potential of its lead candidate, soquelitinib, which is expected to drive stock price appreciation.
- Strong Stock Performance: CRVS shares have surged over 400% in the past 12 months, reflecting strong market confidence in the company's future, particularly as the current valuation does not fully capture soquelitinib's potential in treating atopic dermatitis and other autoimmune conditions.
- Clinical Trial Catalysts: The analyst noted that soquelitinib's development for atopic dermatitis is significant, with multiple clinical trial catalysts scheduled over the next 12-18 months, which could further propel the stock price upward.
- Long-Term Growth Potential: Although soquelitinib is still in early development, the analyst envisions CRVS gradually maturing into a large-cap biotech company, as market demand for next-gen therapies continues to expand.
See More
Goldman Sachs Bullish on Corvus Pharmaceuticals Stock Outlook
- Goldman Sachs Rating Boost: Goldman Sachs initiates coverage of Corvus Pharmaceuticals with a buy rating and sets a $40 price target, implying a 166% upside from Thursday's close, reflecting strong market confidence in the company's new drug potential.
- Stock Price Surge: Following Goldman Sachs' report, Corvus Pharmaceuticals' stock rose approximately 9%, indicating investor enthusiasm for its new oral medication soquelitinib, which is expected to address a significant market need.
- Strong Market Demand: The global market for moderate-to-severe atopic dermatitis treatments is projected to exceed $24 billion by 2035, highlighting Corvus Pharmaceuticals' strategic positioning in this rapidly growing sector, especially as demand for non-steroidal therapies increases.
- Clinical Trial Success: Soquelitinib demonstrated positive effects in 75% of participants during early-stage clinical trials, showcasing its significant efficacy in a competitive dermatological treatment landscape, further solidifying Goldman Sachs' bullish outlook on the stock.
See More
Latest Ratings and Outlook from Wall Street
- Apple Maintained as Buy: Bank of America reiterated its buy rating on Apple (AAPL), labeling it as the “highest quality name,” and despite underperformance year-to-date, it is still viewed as a high-quality compounder supported by resilient services growth and a healthy product cycle.
- Semiconductor Sector Pressure: Mizuho downgraded NXP Semiconductors (NXPI) to sell, citing its significant exposure to the auto sector as a headwind, with the 2026 auto outlook softened by geopolitical and macroeconomic challenges.
- Netflix's Solid Performance: Bank of America reaffirmed its buy rating on Netflix following a solid first quarter that modestly beat forecasts, with management reiterating three core priorities that align with their ongoing strategic focus and competitive positioning in the market.
- Petrobras Rating Upgrade: Bank of America upgraded Petrobras (PBR) from neutral to buy, highlighting its robust cash flow generation and low double-digit dividend yield, which reduces the risk of a potential revision to its dividend policy in a high oil price environment.
See More
Corvus Pharmaceuticals Appoints New Board Member
- New Board Member: Corvus Pharmaceuticals has appointed Dr. Andrew C. Chan to its Board of Directors, bringing 25 years of experience from Genentech where he led the development of several FDA-approved drugs, enhancing the company's expertise in immune modulation and cancer treatment.
- Enhanced Scientific Perspective: Dr. Chan's addition is expected to elevate the scientific perspective of the board, supporting the company's strategy in ITK inhibition and immune modulation, which is anticipated to drive the development of soquelitinib and strengthen market competitiveness in treating immune diseases and cancer.
- Rich Professional Background: Dr. Chan's deep expertise in immunology and his remarkable achievements in academia and industry, particularly in T cell signaling, will provide significant strategic value to Corvus's research and development efforts.
- Clinical Trial Prospects: Soquelitinib, an investigational oral small molecule drug, is currently undergoing a registration Phase 3 clinical trial for relapsed/refractory PTCL, expected to offer a new treatment mechanism for various immune diseases, further solidifying the company's market position.
See More
Corvus Pharmaceuticals Unveils New Drug Data at SID Meeting
- Clinical Trial Progress: Corvus Pharmaceuticals will showcase Phase 1 clinical trial data for soquelitinib at the investor meeting on May 14, 2026, including new immunologic and biomarker data supporting drug-free remissions, which could enhance the company's competitive position in dermatological treatments.
- Key Meeting Arrangement: The meeting will be hosted by CEO Richard A. Miller, M.D., featuring experts from Stanford University discussing the drug's mechanism and its application in atopic dermatitis, likely attracting significant attention from investors and analysts, thereby boosting market confidence.
- Financial Reporting Schedule: The company plans to release its first-quarter 2026 financial results on May 7, 2026, without a conference call, indicating a focus on direct communication with investors, which may influence shareholder expectations regarding the company's future performance.
- New Drug Development Outlook: As a selective ITK inhibitor, soquelitinib is undergoing multiple clinical trials, and if successful, it could open new market opportunities for the company in immunotherapy, particularly in treating relapsed/refractory PTCL and atopic dermatitis.
See More
Corvus' Oral Therapy Potential Underestimated by Analysts
- Significant Clinical Results: Corvus' Soquelitinib demonstrated impressive early trial results for atopic dermatitis, with 75% of patients achieving at least a 75% improvement and 25% experiencing over 90% improvement, indicating its potential as a leading oral therapy in the market.
- Stock Price Surge: Following a bullish analyst call, shares of Corvus Pharmaceuticals (CRVS) jumped nearly 12% on Friday, breaking above their 50-day moving average for the first time since March 13, reflecting increased market confidence in the potential of its oral drug.
- Goldman Sachs Upgrade: Goldman Sachs initiated coverage of Corvus with a 'Buy' rating and a price target of $40, representing a 138% upside from current levels, highlighting the company's competitive edge in the post-Dupixent atopic dermatitis market.
- Investor Sentiment Shift: Retail sentiment for CRVS on Stocktwits shifted from 'bearish' to 'bullish' with high message volumes, as some users anticipate the stock could climb to $100 over the next 12-18 months, indicating optimism about Corvus' future prospects.
See More
Goldman Sachs Initiates Buy on Corvus with $40 Target
- Goldman Coverage Launch: Goldman Sachs has initiated coverage on Corvus Pharmaceuticals (CRVS) with a Buy rating and a $40 price target, with analyst Paul Choi highlighting the pipeline potential of its lead candidate, soquelitinib, which is expected to drive stock price appreciation.
- Strong Stock Performance: CRVS shares have surged over 400% in the past 12 months, reflecting strong market confidence in the company's future, particularly as the current valuation does not fully capture soquelitinib's potential in treating atopic dermatitis and other autoimmune conditions.
- Clinical Trial Catalysts: The analyst noted that soquelitinib's development for atopic dermatitis is significant, with multiple clinical trial catalysts scheduled over the next 12-18 months, which could further propel the stock price upward.
- Long-Term Growth Potential: Although soquelitinib is still in early development, the analyst envisions CRVS gradually maturing into a large-cap biotech company, as market demand for next-gen therapies continues to expand.
See More
Goldman Sachs Bullish on Corvus Pharmaceuticals Stock Outlook
- Goldman Sachs Rating Boost: Goldman Sachs initiates coverage of Corvus Pharmaceuticals with a buy rating and sets a $40 price target, implying a 166% upside from Thursday's close, reflecting strong market confidence in the company's new drug potential.
- Stock Price Surge: Following Goldman Sachs' report, Corvus Pharmaceuticals' stock rose approximately 9%, indicating investor enthusiasm for its new oral medication soquelitinib, which is expected to address a significant market need.
- Strong Market Demand: The global market for moderate-to-severe atopic dermatitis treatments is projected to exceed $24 billion by 2035, highlighting Corvus Pharmaceuticals' strategic positioning in this rapidly growing sector, especially as demand for non-steroidal therapies increases.
- Clinical Trial Success: Soquelitinib demonstrated positive effects in 75% of participants during early-stage clinical trials, showcasing its significant efficacy in a competitive dermatological treatment landscape, further solidifying Goldman Sachs' bullish outlook on the stock.
See More
Latest Ratings and Outlook from Wall Street
- Apple Maintained as Buy: Bank of America reiterated its buy rating on Apple (AAPL), labeling it as the “highest quality name,” and despite underperformance year-to-date, it is still viewed as a high-quality compounder supported by resilient services growth and a healthy product cycle.
- Semiconductor Sector Pressure: Mizuho downgraded NXP Semiconductors (NXPI) to sell, citing its significant exposure to the auto sector as a headwind, with the 2026 auto outlook softened by geopolitical and macroeconomic challenges.
- Netflix's Solid Performance: Bank of America reaffirmed its buy rating on Netflix following a solid first quarter that modestly beat forecasts, with management reiterating three core priorities that align with their ongoing strategic focus and competitive positioning in the market.
- Petrobras Rating Upgrade: Bank of America upgraded Petrobras (PBR) from neutral to buy, highlighting its robust cash flow generation and low double-digit dividend yield, which reduces the risk of a potential revision to its dividend policy in a high oil price environment.
See More
